RSS   Newsletter   Contact   Advertise with us

NeuroVive names Magnus Hansson as chief medical officer

Staff writer | Lund, Sweden | October 26, 2015
NeuroViveOctober 26, 2015, Lund, Sweden - NeuroVive Pharmaceutical AB (publ), a mitochondrial medicine company, announces that Magnus Hansson will be appointed as chief medical officer, effective January 1, 2016.
Dr. Hansson is a long-standing member of NeuroVive's scientific team, serving as the primary clinical scientist for the CicloMulsion studies.

Parallel to his previous part-time position at NeuroVive, Dr. Hansson has been serving as a consultant physician and associate professor in medical imaging and physiology at Skane University Hospital, Sweden.

Dr. Hansson received his medical degree and PhD in Experimental brain research from Lund University, Sweden and has authored more than 30 scientific publications and 10 patent applications.